Updates on Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Adenocarcinoma.

Mortality after the diagnosis of pancreatic ductal adenocarcinoma remains high for all patients. The role of multimodal therapy, including surgical resection and systemic chemotherapy, has been well established. Neoadjuvant treatment strategies continue to be used in resectable and borderline resectable PDAC. Results from ongoing or recently completed trials will continue to provide valuable insight into the management of patients with resectable and borderline resectable PDAC. Advances in the outcomes for this difficult disease and therefore the focus of futures studies should include a better understanding of tumor biology and markers, novel treatment agents, and combination treatment strategies.